TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
31.15
+0.83 (2.74%)
At close: Nov 20, 2024, 4:00 PM
31.86
+0.71 (2.28%)
Pre-market: Nov 21, 2024, 7:21 AM EST
TG Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TG Therapeutics stock have an average target of 37.67, with a low estimate of 22 and a high estimate of 55. The average target predicts an increase of 20.93% from the current stock price of 31.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TGTX stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +76.57% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -29.37% | Nov 5, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +60.51% | Oct 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +57.30% | Sep 18, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $29 → $34 | Strong Buy | Maintains | $29 → $34 | +9.15% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
335.86M
from 233.66M
Increased by 43.74%
Revenue Next Year
551.82M
from 335.86M
Increased by 64.30%
EPS This Year
0.15
from 0.09
Increased by 68.86%
EPS Next Year
0.99
from 0.15
Increased by 556.38%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 427.8M | 627.4M | 948.5M | ||
| Avg | 335.9M | 551.8M | 760.8M | ||
| Low | 308.2M | 480.2M | 627.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 83.1% | 86.8% | 71.9% | ||
| Avg | 43.7% | 64.3% | 37.9% | ||
| Low | 31.9% | 43.0% | 13.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.70 | 1.37 | 3.31 | ||
| Avg | 0.15 | 0.99 | 1.84 | ||
| Low | 0.01 | 0.67 | 0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 688.1% | 805.6% | 234.3% | ||
| Avg | 68.9% | 556.4% | 85.6% | ||
| Low | -89.0% | 342.1% | -56.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.